GeneCopoeia, Inc. is a manufacturer and provider of genomics and proteomics products and services for academic and governmental research institutes, pharmaceutical and biotechnology industry. GeneCopoeia, Inc. (GCI) is a biotechnology start-up company specialized in genomic-scale gene expression vector construction, gene expression, and protein expression/purification. The company has developed a unique, proprietary technology for refolding proteins expressed in E. coli as inclusion bodies. GCI utilizes its refolding technology to refold/purify proteins expressed as inclusion bodies in E. coli for developing important drug targets and protein drugs. GCI has developed a healthy protein drug pipeline such as the recombinant p53-fusion protein for cancer currently funded by a SBIR Phase II, and a mini-Plasmin protein for thromboembolic diseases currently funded by a SBIR Phase I
